VIP Molecular Structure & Chemistry

Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide exhibiting a sophisticated VIP molecular structure and chemistry, which underpins its broad engagement in various physiological systems, making it a focal point in contemporary research. Understanding the precise molecular configuration, synthesis pathways, degradation mechanisms, and receptor binding characteristics of VIP is paramount for researchers seeking to elucidate its biological roles and potential utility in experimental models.

As a key member of the secretin/glucagon peptide family, VIP’s role as a neuropeptide and neuromodulator has attracted significant scientific inquiry. Its involvement in modulating immune responses and influencing vascular tone positions it as a compound of interest for investigations into complex biological processes. The extensive body of scientific literature, with numerous PubMed publications indexed, underscores the widespread research on VIP. Furthermore, its biological relevance is highlighted by several registered studies on ClinicalTrials.gov, which serve as a repository for investigations into various compounds, including those with mechanisms related to VIP, for a range of research questions. These ongoing and completed studies reflect the peptide’s significance in dissecting fundamental biological pathways relevant to immune and vascular system function.

Vasoactive Intestinal Peptide (VIP): Core Molecular Identity

Vasoactive Intestinal Peptide (VIP) stands as a prominent member of the secretin/glucagon superfamily, an extensively studied neuropeptide characterized by its pleiotropic actions across numerous physiological systems. Discovered originally in porcine duodenal extracts, VIP quickly garnered significant research interest due to its potent vasodilatory properties and its widespread distribution throughout the central and peripheral nervous systems, as well as in endocrine cells and immune tissues. Its designation as a “vasoactive intestinal peptide” reflects its initial identification and a key aspect of its biological activity, though subsequent research has unveiled a far broader spectrum of roles, positioning it as a critical regulator in immunological, cardiovascular, gastrointestinal, and neuroendocrine contexts. The characterization of VIP as a 28-amino acid peptide has facilitated extensive investigations into its molecular structure, receptor interactions, and the complex signaling cascades it orchestrates.

The ubiquity of VIP and its multifaceted functional profile make it a compelling subject in diverse research fields. From its origins as a gut hormone, VIP’s role has expanded to encompass neuroprotection, anti-inflammatory actions, regulation of circadian rhythms, and modulation of various immune responses. This broad biological reach is a testament to the evolutionary conservation of its structure and its fundamental importance in maintaining physiological homeostasis. Researchers often utilize synthetic VIP and its analogs to dissect these intricate pathways, seeking to understand the precise molecular mechanisms underpinning its diverse effects. The availability of high-purity research-grade peptides is paramount for such studies, ensuring reliable and reproducible experimental outcomes.

The extensive body of literature on VIP underscores its significance in biomedical research. PubMed currently indexes numerous publications exploring various facets of VIP, ranging from its basic biochemistry to its complex roles in disease models, reflecting sustained global interest. Furthermore, several registered studies on ClinicalTrials.gov highlight the ongoing translational research efforts to understand VIP’s potential relevance in human health, though these investigations remain strictly within the confines of clinical research and are not indicative of approved applications or safety for human use. For a broader understanding of the diverse molecules utilized in such investigations, insights into what are research peptides can provide valuable context.

Classification and Structural Homology

VIP belongs to the secretin/glucagon superfamily of peptides, which includes other structurally and functionally related molecules such as glucagon, secretin, gastric inhibitory polypeptide (GIP), growth hormone-releasing hormone (GHRH), and pituitary adenylate cyclase-activating polypeptide (PACAP). This superfamily is characterized by a conserved general architecture and a shared mechanism of action, primarily involving G protein-coupled receptors (GPCRs) that activate adenylyl cyclase and increase intracellular cyclic AMP (cAMP) levels. VIP exhibits significant sequence homology with PACAP, particularly in its N-terminal region, accounting for their often overlapping, though distinct, pharmacological profiles. This structural kinship allows for comparative research into receptor specificity and downstream signaling pathways, aiding in the development of selective research tools.

The functional diversity of VIP is intrinsically linked to its ability to interact with specific high-affinity receptors, which are widely expressed across different cell types and tissues. These interactions initiate a cascade of intracellular events that translate into the observed biological responses. Understanding the core molecular identity of VIP—its precise amino acid sequence, conformational preferences, and how these attributes dictate its engagement with its cognate receptors—is foundational for any rigorous investigation into its roles in immune modulation, neuroprotection, smooth muscle relaxation, and glandular secretion. The precise control over peptide synthesis and purification allows researchers to explore these fundamental molecular interactions with high fidelity, ensuring the integrity of their experimental designs.

Primary Structure and Amino Acid Sequence of VIP

The primary structure of Vasoactive Intestinal Peptide (VIP) is defined by its precise sequence of 28 amino acids. This linear arrangement of residues is highly conserved across various species, underscoring its fundamental biological importance throughout evolution. The sequence typically begins with a histidine residue at the N-terminus and concludes with a methionine amide at the C-terminus. The amidation of the C-terminal methionine is a critical post-translational modification that significantly contributes to the peptide’s biological activity and metabolic stability in research models, preventing enzymatic degradation from the C-terminal end and facilitating effective receptor binding. The absence of this amidation can drastically reduce or abolish VIP’s potency, making it a crucial consideration in the design and synthesis of research-grade VIP.

The specific amino acid sequence of human VIP is: H-S-D-A-V-F-T-D-N-Y-T-R-L-R-K-Q-M-A-V-K-K-Y-L-N-S-I-L-N-amide. This sequence provides the blueprint for its three-dimensional structure and, consequently, its functional interactions. Key residues within this sequence are known to be essential for receptor recognition and activation. For instance, the N-terminal region, particularly His1, Ser2, and Asp3, has been identified as crucial for high-affinity binding to VIP receptors. Substitutions or deletions in these critical N-terminal residues can severely impair the peptide’s ability to elicit biological responses, highlighting the precise molecular requirements for its pharmacological activity. Research into VIP analogs often involves strategic modifications of specific residues to enhance selectivity for particular receptor subtypes or to improve pharmacokinetic properties.

VIP’s membership in the secretin/glucagon superfamily is reflected in its sequence homology with other members. Although each peptide in the superfamily possesses distinct biological activities and receptor specificities, they share common motifs that contribute to their overall structural integrity and mechanism of action. This shared ancestry allows for comparative sequence analysis, which can provide insights into evolutionary pressures and functional divergences among these related peptides. For instance, comparisons with Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) reveal significant identity in the N-terminal domain, explaining some degree of cross-reactivity with VIP receptors, particularly VPAC1 and VPAC2.

The Significance of Specific Residues

The integrity of VIP’s primary structure is paramount for its biological function. The N-terminal portion (residues 1-10) is largely responsible for receptor binding and activation, with the first five residues being particularly critical for high-affinity interaction. Changes in these N-terminal amino acids can lead to significant alterations in binding affinity and signaling efficacy. For example, the His1 residue plays a vital role in initiating the conformational changes within the receptor that lead to G-protein activation. Moving towards the C-terminus, residues beyond position 15 contribute more to the overall structural stability and receptor specificity rather than direct binding initiation.

Post-Translational Modifications

Beyond the linear sequence, the C-terminal amidation is the most critical post-translational modification for VIP. This modification is catalyzed by peptidylglycine alpha-amidating monooxygenase (PAM) and involves the conversion of a C-terminal glycine-extended precursor into the mature peptide with an amide group. This amidation stabilizes the peptide against carboxypeptidase degradation and is essential for its full biological potency. In research, synthetic VIP must faithfully replicate this amidation to ensure the peptide’s activity mirrors that of endogenous VIP. Other potential modifications, such as phosphorylation or glycosylation, are less commonly reported or studied for VIP compared to its C-terminal amidation, but remain areas of ongoing investigation for various peptide hormones.

Secondary and Tertiary Conformation of VIP

The biological activity of Vasoactive Intestinal Peptide (VIP) is not solely dictated by its primary amino acid sequence but is profoundly influenced by its three-dimensional structure. In solution, VIP is often described as possessing a dynamic and flexible conformation, especially in aqueous environments. However, upon interaction with its target receptors or lipid membranes, VIP undergoes significant conformational changes, adopting more ordered secondary and tertiary structures that are critical for effective binding and signal transduction. This conformational plasticity allows VIP to adapt to different microenvironments and efficiently engage with its cognate G protein-coupled receptors (GPCRs), VPAC1 and VPAC2, facilitating the complex molecular recognition processes inherent to neuropeptide signaling.

The predominant secondary structure adopted by VIP in membrane-mimetic environments or when bound to its receptors is an alpha-helix. Studies utilizing techniques such as circular dichroism (CD) spectroscopy have consistently demonstrated that VIP, largely unstructured in aqueous buffer, gains a substantial alpha-helical content in the presence of detergents, organic solvents, or lipid vesicles that mimic cellular membranes. This induced helical structure is particularly pronounced in the central and C-terminal regions of the peptide (approximately residues 6-28), forming an amphipathic helix where hydrophobic residues orient towards the lipid bilayer or receptor transmembrane domains, while hydrophilic residues face the aqueous environment or the receptor’s extracellular loops. This transition from a random coil to a more ordered helical conformation is a common theme among GPCR-binding peptides and is crucial for receptor activation.

While VIP does not typically form a stable, rigid tertiary structure in isolation like globular proteins, its receptor-bound state represents a highly specific and functional tertiary arrangement. The amphipathic alpha-helix is believed to insert into the lipid bilayer or directly interact with the extracellular domains and transmembrane helices of the VPAC receptors. This interaction is thought to stabilize the active conformation of the receptor, leading to downstream G-protein coupling and signal transduction. The N-terminal region of VIP, though contributing less to the overall helical content, plays a critical role in receptor recognition and initial binding events, potentially acting as a “key” that initiates the conformational changes necessary for the more structured C-terminal helix to fully engage with the receptor’s binding pocket.

Techniques for Conformational Elucidation

Understanding the secondary and tertiary conformation of VIP relies on a suite of sophisticated biophysical techniques. These methods provide insights into the peptide’s structural preferences under various conditions:

Circular Dichroism (CD) Spectroscopy: This technique is widely used to determine the relative content of different secondary structures (e.g., alpha-helix, beta-sheet, random coil) in peptides. CD spectra of VIP in different solvent environments or in the presence of membrane mimetics clearly show the induction of alpha-helical content.
Nuclear Magnetic Resonance (NMR) Spectroscopy: High-resolution NMR provides detailed information about the three-dimensional structure of peptides in solution. While challenging for larger, flexible peptides like VIP, specific NMR experiments can reveal regions of helical stability and inter-residue contacts. Solid-state NMR can also be employed to study VIP’s conformation within lipid bilayers.
X-ray Crystallography: While obtaining crystals of flexible peptides like VIP in isolation is difficult, co-crystallization with receptor fragments or specific binding proteins, or receptor-ligand complexes, can provide atomic-resolution structures of VIP in its bound state. Such structures offer invaluable insights into the precise molecular interactions at the receptor interface.
Molecular Dynamics Simulations: Computational approaches complement experimental data by modeling the dynamic behavior of VIP in various environments, predicting conformational transitions, and simulating its interaction with membranes or receptors. These simulations can help bridge gaps in experimental data and propose mechanisms for conformational changes.

Conformational Changes and Receptor Activation

The dynamic nature of VIP’s conformation is key to its biological efficacy. The transition from a flexible, disordered state in solution to a more ordered alpha-helical structure upon membrane or receptor binding is a critical step in receptor activation. This induced fit mechanism ensures specificity and efficiency in signaling. Research indicates that the stabilization of the alpha-helical conformation, particularly in the C-terminal region, is essential for optimal interaction with the extracellular and transmembrane domains of the VPAC receptors. The N-terminal segment, while possibly less structured, serves as the initial recognition motif, guiding the peptide to its binding site and facilitating the subsequent structural reordering that ultimately leads to downstream G-protein activation and cellular responses. Understanding these intricate conformational dynamics is crucial for rational design of VIP analogs with altered binding or signaling properties.

Chemical Synthesis and Modifications of VIP Analogs

The study of Vasoactive Intestinal Peptide (VIP) and its diverse biological roles has been significantly advanced by the ability to chemically synthesize the peptide and its various analogs. Chemical synthesis provides researchers with precise control over the amino acid sequence, allowing for the generation of VIP in high purity and sufficient quantities for rigorous experimentation. The predominant method for synthesizing VIP and similar peptides is Solid-Phase Peptide Synthesis (SPPS), a robust and well-established technique that revolutionized peptide chemistry. SPPS involves the stepwise assembly of amino acids onto an insoluble polymeric resin, offering numerous advantages including simplified purification steps, facile automation, and the ability to incorporate non-natural amino acids or isotopic labels.

The process of SPPS typically begins by attaching the C-terminal amino acid to a resin. Subsequent amino acids are then coupled one by one in a protected form, with deprotection steps in between to expose the reactive N-terminus for the next coupling reaction. This iterative cycle of coupling and deprotection continues until the full peptide sequence is assembled. Following synthesis, the peptide is cleaved from the resin and simultaneously deprotected using strong acids (e.g., trifluoroacetic acid). The crude peptide is then purified, most commonly by High-Performance Liquid Chromatography (HPLC), to isolate the desired product from truncated sequences, deleted peptides, and other impurities. Rigorous quality control, including mass spectrometry and amino acid analysis, is essential to confirm the identity and purity of the synthetic VIP, ensuring reliable research outcomes. This comprehensive approach to quality is often detailed in a Certificate of Analysis (CoA).

The ability to chemically synthesize VIP opens avenues for creating a vast array of analogs, which are invaluable tools for elucidating structure-activity relationships, improving pharmacokinetic profiles, and developing selective receptor agonists or antagonists for research purposes. These modifications can involve a range of chemical alterations designed to address specific research questions or overcome inherent limitations of native VIP. For instance, the native peptide’s short half-life due to enzymatic degradation often necessitates modifications to enhance its metabolic stability, allowing for sustained activity in in vivo research models.

Common Modifications and Their Research Applications

VIP analogs are generated through various modifications, each serving distinct research objectives:

Amino Acid Substitutions: Replacing one or more amino acids in the native sequence with different natural or unnatural amino acids allows researchers to probe the importance of specific residues for receptor binding, activation, and selectivity. For example, substitutions can enhance affinity for VPAC1 over VPAC2, or vice versa, creating subtype-selective tools for dissecting receptor-specific signaling pathways.
N-Terminal Modifications: Acylation (e.g., acetylation) or the addition of various chemical moieties to the N-terminus can sometimes improve metabolic stability by protecting against aminopeptidase degradation, or modify receptor interactions.
C-Terminal Modifications: While the native VIP is C-terminally amidated, alternative modifications such as the addition of a free carboxylic acid or other groups can be explored to understand the functional significance of this natural amidation or to attach reporter molecules.
PEGylation: Covalent attachment of polyethylene glycol (PEG) chains to VIP can significantly increase its hydrodynamic radius, thereby reducing renal clearance and improving resistance to proteolytic enzymes. This modification is widely used in pharmacokinetic studies to extend the systemic exposure of peptides in research models.
Fluorescent and Biotin Labels: Attaching fluorescent tags (e.g., fluorescein, rhodamine) or biotin to VIP allows for its visualization, tracking, and detection in cellular and tissue-based assays. These labeled analogs are crucial for receptor localization studies, binding assays, and flow cytometry.
Isotopic Labeling: Incorporation of stable isotopes (e.g., ²H, ¹³C, ¹⁵N) can be used for NMR spectroscopy to study conformational dynamics or for mass spectrometry-based quantitative proteomics to trace peptide metabolism and distribution in complex biological systems.
Cyclization: Introducing disulfide bridges or lactam bridges can constrain the peptide into a more rigid conformation, potentially enhancing receptor selectivity or stability by limiting unfavorable conformational sampling.

Challenges in Analog Design and Synthesis

While chemical synthesis offers immense flexibility, the design and synthesis of effective VIP analogs present several challenges. Maintaining biological activity while improving stability or selectivity requires a deep understanding of VIP-receptor interactions. Steric hindrance, hydrophobicity, and charge distribution must be carefully considered when introducing modifications. Furthermore, the synthesis of long, complex peptides with multiple modifications can be technically demanding, potentially leading to lower yields and requiring extensive purification protocols to achieve research-grade purity. The rigorous characterization of each analog is indispensable to ensure its identity, purity, and functional integrity for accurate interpretation of experimental results.

Pharmacokinetics and Metabolic Stability of VIP in Research Models

The utility of Vasoactive Intestinal Peptide (VIP) in various research applications, particularly those involving in vivo models, is significantly influenced by its pharmacokinetic profile and metabolic stability. Native VIP, like many endogenous peptides, exhibits a relatively short half-life in biological systems, primarily due to rapid enzymatic degradation. This characteristic necessitates careful consideration in experimental design, as sustained physiological effects require either continuous administration or the development of metabolically stable analogs. Understanding the mechanisms of VIP degradation and clearance is crucial for optimizing its research applications and for informing the rational design of modified peptides with enhanced properties for investigational studies.

Upon administration into research models, VIP is rapidly cleared from the circulation. Its short half-life, typically on the order of minutes, is attributed to the widespread presence of various peptidases and proteases throughout the body. Key enzymes involved in VIP metabolism include neutral endopeptidase (NEP, also known as neprilysin, EC 3.4.24.11), dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5), and to a lesser extent, endopeptidases like angiotensin-converting enzyme (ACE) and elastase. NEP is particularly active in cleaving VIP at specific internal peptide bonds, while DPP-IV removes dipeptides from the N-terminus if the second residue is proline or alanine (though VIP lacks proline at this position, it is still susceptible to other aminopeptidases that might be part of the DPP-IV complex or activity profile, or other related enzymes). This rapid enzymatic breakdown means that native VIP typically elicits transient effects in systemic research models, unless administered continuously.

Beyond enzymatic degradation, VIP’s clearance also involves renal filtration and uptake by various tissues expressing VIP receptors or non-specific peptide transporters. The distribution of VIP is extensive, reflecting the widespread presence of its receptors. After systemic administration, VIP can reach a variety of organs, including the kidney, liver, lung, and gastrointestinal tract, as well as the central nervous system (albeit with limited penetration of the intact blood-brain barrier). The precise tissue distribution and subsequent metabolic fate can vary depending on the route of administration, the physiological state of the research model, and the specific binding affinities to its receptors and other non-specific binding sites. Investigating these parameters often requires sensitive analytical techniques, such as radioimmunoassays (RIAs) or liquid chromatography-mass spectrometry (LC-MS/MS), to quantify VIP levels in biological samples.

Strategies for Enhancing Metabolic Stability in Research

Frequently Asked Questions

What is the primary amino acid sequence of VIP?

The primary structure of Vasoactive Intestinal Peptide (VIP) consists of 28 amino acids. The sequence is His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2. This specific sequence is critical for its biological activity and receptor binding, with the C-terminus being amidated, a common post-translational modification for many neuropeptides.

How is VIP typically synthesized for research purposes?

For research applications, Vasoactive Intestinal Peptide (VIP) is predominantly synthesized using solid-phase peptide synthesis (SPPS) techniques. This method involves sequentially adding protected amino acid residues to a growing peptide chain anchored to an insoluble resin. After assembly, the peptide is cleaved from the resin and deprotected, followed by extensive purification steps, often involving high-performance liquid chromatography (HPLC), to achieve the high purity required for rigorous scientific investigations.

What are the main receptor types that VIP interacts with?

VIP exerts its biological effects primarily through two G protein-coupled receptors (GPCRs): VPAC1 (Vasoactive Intestinal Peptide Receptor Type 1) and VPAC2 (Vasoactive Intestinal Peptide Receptor Type 2). These receptors belong to the class B GPCR family and are broadly distributed across various tissues and cell types. VIP also exhibits some affinity for the PAC1 receptor, though generally with lower potency compared to its primary ligand, pituitary adenylate cyclase-activating polypeptide (PACAP).

How is VIP degradation studied in research models?

Research into VIP degradation often involves *in vitro* studies using tissue homogenates, plasma, or purified enzymes (e.g., peptidases like neutral endopeptidase 24.11, dipeptidyl peptidase IV) to identify specific cleavage sites and characterize degradation products. *In vivo* studies in animal models may involve administering VIP and sampling biological fluids over time to measure metabolite formation and assess the peptide’s half-life, frequently using mass spectrometry or immunoassay techniques to quantify VIP and its fragments.

What analytical methods are commonly used to characterize VIP?

Common analytical methods for characterizing VIP include high-performance liquid chromatography (HPLC) for purity assessment and purification, mass spectrometry (MS) (e.g., LC-MS, MALDI-TOF) for molecular weight verification and sequence confirmation, and nuclear magnetic resonance (NMR) spectroscopy for detailed structural elucidation, including conformation in solution. Circular dichroism (CD) spectroscopy is also employed to assess secondary structure elements like alpha-helical content.

Why is VIP studied in immune system research?

VIP is studied in immune system research due to its observed immunomodulatory properties. Research indicates VIP can influence the proliferation, differentiation, and cytokine production of various immune cells, including T cells, macrophages, and dendritic cells. Investigations often focus on its potential to modulate inflammatory responses, shift cytokine profiles, and impact immune cell trafficking in various experimental models of immune challenge or dysregulation.

What are the key challenges in studying VIP’s molecular structure?

Key challenges in studying VIP’s molecular structure include its inherent flexibility as a relatively small, linear peptide, which can make obtaining high-resolution structural data, such as from X-ray crystallography, particularly difficult without co-crystallization with a binding partner. Furthermore, its dynamic interactions with various membrane-bound receptors and its susceptibility to enzymatic degradation necessitate careful experimental design to maintain structural integrity during analysis.

What are common considerations for storing VIP peptides in a laboratory?

Common considerations for storing VIP peptides in a laboratory include ensuring the peptide is stored in a lyophilized (freeze-dried) state at very low temperatures, typically -20°C or -80°C, to prevent degradation. When reconstituted, stock solutions should be prepared in appropriate, sterile buffers, often with a carrier protein (e.g., bovine serum albumin) to prevent adsorption to plastic surfaces, and aliquoted to minimize freeze-thaw cycles, which can compromise peptide integrity.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.

VIP Molecular Structure & Chemistry — Research Reference